Terray Therapeutics utilizes a novel spatially encoded screening and optimization platform (tArray) to develop treatments for historically intractable causes of human disease. The company is based in Pasadena, California.

Our Leadership Team

Jacob Berlin, CEO

Prior to co-founding Terray Therapeutics, Jacob ran an NIH-funded lab at City of Hope, where he was an associate professor. Jacob received his PhD in organic chemistry from CalTech where he studied with Nobel Laureate Bob Grubbs. Jacob’s postdoctoral training focused on synthetic chemistry and nanotechnology at MIT and Rice University.  He received a BA in chemistry from Harvard University (magna cum laude).

Gregory Copeland, CSO

Prior to co-founding Terray Therapeutics, Greg spent 6 years working on the foundational science of Terray Therapeutics as a staff scientist at City of Hope. Prior to City of Hope, Greg was a Senior Research chemist at Merck. He received his PhD in organic chemistry from Boston College and completed his postdoctoral training at Harvard University.

Eli Berlin, CBO

Prior to co-founding Terray Therapeutics, Eli spent more than 10 years working in private equity. Most recently, Eli worked at Parthenon Capital Partners, an operationally focused private equity firm. Prior to Parthenon, Eli worked at Irving Place Capital and Lehman Brothers. He holds an MBA from Stanford University and a BA with honors from the London School of Economics.

Our Investors